Obesity Pill Races Heats Up as Novo, Roche and Terns Share Data - BioSpace
Novo Nordisk, Roche, and Terns Pharmaceuticals presented data on their oral obesity candidates at the European Association for the Study of Diabetes meeting, showing weight loss figures of 4%, 4.9%, and 6.1% respectively. Roche's CT-996 led in efficacy but had high adverse event rates, while Novo's amycretin faced manufacturing challenges. Terns' TERN-601 showed potential for high efficacy and tolerability, though it requires further Phase II data.
Reference News
Novo Nordisk, Roche, and Terns Pharmaceuticals presented data on their oral obesity candidates at the European Association for the Study of Diabetes meeting, showing weight loss figures of 4%, 4.9%, and 6.1% respectively. Roche's CT-996 led in efficacy but had high adverse event rates, while Novo's amycretin faced manufacturing challenges. Terns' TERN-601 showed potential for high efficacy and tolerability, though it requires further Phase II data.